Hindustan Times Floodgates for cheap weight-loss drugs open as key patent expires
As Novo Nordisk’s patent on semaglutide expires, India braces for an influx of over 50 generic weight-loss drugs, promising lower prices and broader access.
As Novo Nordisk’s patent on semaglutide expires, India braces for an influx of over 50 generic weight-loss drugs, promising lower prices and broader access.